(Q24245147)

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

What is new since the last (1999) Canadian Asthma Consensus Guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Mucosal inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

ABC of Asthma. Treatment of chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Clinical trials: are these your patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Efficacy of antileukotriene agents in asthma management

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Antagonism of long-acting beta2-adrenoceptor agonism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

The prospects for long-term intervention in asthma with antileukotrienes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Active cigarette smoking and asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Treatment of bronchial asthma using a new adjustable combination treatment plan: Asthma Control Plan (ATACO)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Leukotriene receptor antagonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

New combination therapies for asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Guidelines for the evaluation of impairment/disability in patients with asthma. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

The role of leukotriene modifiers in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effect of the addition of montelukast to inhaled fluticasone propionate on airway inflammation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Expression and release of interleukin-8 by human airway smooth muscle cells: inhibition by Th-2 cytokines and corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

New insights into the understanding of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. National Heart, Lung, and Blood Institute

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Pharmacokinetic profile of zafirlukast

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Clinical evidence with montelukast in the management of chronic childhood asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Inhaled corticosteroid doses in asthma: an evidence-based approach.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003137.PUB2

7 January 2021